How should cefalexin (Keflex) be dosed for uncomplicated cellulitis, and what alternative antibiotics are recommended for patients with β‑lactam allergy or suspected MRSA infection?

Cephalexin (Keflex) for Uncomplicated Cellulitis

For uncomplicated, nonpurulent cellulitis, prescribe cephalexin 500 mg orally four times daily for 5-10 days, as β-lactams like cephalexin remain the first-line treatment targeting β-hemolytic streptococci, the predominant pathogens in this presentation. 1, 2, 3

Dosing Regimen

Standard Dosing

• Adults: Cephalexin 500 mg orally every 6 hours (four times daily) for uncomplicated skin and soft tissue infections 3
• Pediatric patients: 25-50 mg/kg/day divided into four doses 3
• Duration: 5-10 days, individualized based on clinical response 2

Alternative Dosing Considerations

• For mild-moderate infections, 500 mg every 12 hours may be adequate 3
• Emerging evidence suggests high-dose cephalexin (1000 mg four times daily) may reduce treatment failure rates (12.9% vs 3.2%) though with increased minor adverse effects 4
• Daily doses should remain within 1-4 grams per day 3

Clinical Decision Algorithm

Step 1: Classify the Cellulitis Type

Nonpurulent cellulitis (no drainage, exudate, or abscess):

• Empirically treat for β-hemolytic streptococci with cephalexin 2
• MRSA coverage is NOT routinely needed initially 2
• Add MRSA coverage only if patient fails to respond to β-lactam therapy or has systemic toxicity 2

Purulent cellulitis (drainage/exudate without drainable abscess):

• Empirically cover for CA-MRSA pending cultures 2
• β-hemolytic streptococcal coverage is likely unnecessary 2

Step 2: Assess for MRSA Risk Factors

Add MRSA coverage if:

• No clinical improvement after 48-72 hours on cephalexin 2
• Signs of systemic toxicity present 2
• Purulent drainage without abscess 2

Alternatives for Special Populations

β-Lactam Allergy

For patients with penicillin allergy history:

• Cephalexin can be safely used in most cases, as cross-reactivity between penicillins and cephalosporins is <5% and primarily occurs with shared R1 side chains 5, 6
• Cephalexin has unique R1 and R2 side chains that largely rule out cross-reactivity 5
• Exception: Higher cross-reactivity risk exists with amino-penicillin (amoxicillin/ampicillin) allergies 6

For true immediate hypersensitivity reactions (urticaria, angioedema, anaphylaxis):

• Perform skin testing before cephalexin administration 5
• Alternative: Clindamycin 300-450 mg orally four times daily 1, 2

For delayed-type reactions (uncomplicated rash):

• Cephalexin is acceptable under clinical supervision 5

Suspected or Confirmed MRSA

Outpatient oral options:

• Clindamycin 300-450 mg orally four times daily (covers both streptococci and MRSA) 2
• TMP-SMX 1-2 double-strength tablets twice daily PLUS a β-lactam like amoxicillin (for streptococcal coverage) 2
• Doxycycline 100 mg twice daily PLUS a β-lactam 2
• Linezolid 600 mg twice daily (covers both streptococci and MRSA, but expensive) 2

Hospitalized patients with complicated SSTI:

• IV vancomycin 30 mg/kg/day in 2 divided doses 1
• Alternatives: linezolid, daptomycin 4 mg/kg daily, ceftaroline 600 mg twice daily 1, 2
• Duration: 7-14 days 2

Critical Evidence Points

Cephalexin vs. Cephalexin + TMP-SMX

A high-quality 2017 RCT demonstrated that adding TMP-SMX to cephalexin for uncomplicated cellulitis did NOT improve clinical cure rates in the per-protocol analysis (83.5% vs 85.5%, difference -2.0%) 7. This supports using cephalexin monotherapy for nonpurulent cellulitis rather than empirically adding MRSA coverage.

Cephalexin vs. IV Cefazolin

Oral cephalexin is non-inferior to IV cefazolin plus probenecid for uncomplicated mild-moderate SSTIs, with similar failure rates at 72 hours (4.2% vs 6.1%) 8. This supports outpatient oral therapy as first-line.

Common Pitfalls to Avoid

1. Don't empirically cover MRSA in nonpurulent cellulitis - This leads to unnecessary broad-spectrum antibiotic use 2, 7

2. Don't withhold cephalosporins in all penicillin-allergic patients - True cross-reactivity is rare (<5%), and cephalexin has superior efficacy and safety compared to alternatives 5, 6, 9

3. Don't forget to exclude abscess - Point-of-care ultrasound should be considered if there's diagnostic uncertainty, as abscesses require incision and drainage 2, 10

4. Don't diagnose bilateral cellulitis readily - Bilateral presentation is rare and should prompt consideration of alternative diagnoses like venous stasis dermatitis 10

5. Don't use TMP-SMX monotherapy for nonpurulent cellulitis - It lacks adequate streptococcal coverage and should be combined with a β-lactam if used 2